USPTO issued patent US12595252B2 to DISARM Therapeutics, Inc. for inhibitors of SARM1 (a protein involved in axonal degradation) useful for treating and preventing axonal degeneration. The patent covers novel chemical compounds, their compositions, and associated treatment methods.

For pharmaceutical companies developing neurological therapies targeting SARM1 or axonal degeneration, this patent creates potential blocking positions that may require licensing negotiations or alternative compound development strategies. Competitors in the neurodegenerative disease treatment space should conduct freedom-to-operate analyses to assess potential infringement risks.